26 views
# Severe diseases of the cardiovascular System # **Tags:** * The latest drugs for high blood pressure * The risk of cardiovascular disease in the young * Infusion of high blood pressure :::warning Ang mga modernong gamot sa pag-imprenta ay hinahati sa 10 iba't ibang grupo ayon sa kanilang mekanismo ng pagkilos. Pagkatapos suriin ng doktor ang mga reklamo ng pasyente at ang resulta ng mga pagsusuri, nagrereseta siya ng isa o higit pang gamot, na hindi dapat baguhin nang mag-isa. Ang mga gamot sa puso at daluyan ng dugo ay hindi kabilang sa mga puwedeng irekomenda sa kaibigan. Ang maling desisyon ay maaaring magdulot ng malungkot na kahihinatnan. Lahat ng gamot na pampababa ng presyon ng dugo ay kailangan ng reseta. Sa artikulong ito, tinitingnan natin ang kanilang modernong klasipikasyon base sa mga aktibong sangkap at sa paraan ng epekto nito sa katawan. ::: [![](https://cardio-balance-ph.store-best.net/img/7.jpg)](https://cardio-balance-ph.store-best.net) <div style="height:500px;"></div> ## The latest drugs for high blood pressure ## <div class="alert alert-info" role="alert"> Ang presyon ng dugo ay isa sa mga pangunahing indikasyon ng kalusugan, na hindi lamang sumasalamin sa puso at sistema ng sirkulasyon, kundi pati na rin sa aktibidad ng mga bato, mga organo ng endokrin, paggawa ng dugo, at ng sistema ng nerbiyos. Kaya naman, walang isang unibersal na gamot laban sa mataas na presyon ng dugo. Hindi ka basta basta puwedeng pumunta sa botika at magtanong ng 'tableta para sa presyon,' kasi agad na tatanungin ng parmasyutiko – anong gamot ang nireseta sa iyo ng doktor? </div> Severe diseases of the cardiovascular system: your path to a better quality of life Heart problems are more than just a medical diagnosis, they affect your daily life, your activities and your well-being. In severe diseases of the cardiovascular system, it is particularly important to get a competent and sensitive care. Why trust us? Highly qualified Team: Our cardiologists and specialists have years of experience in the treatment of complex heart and vascular diseases. Modern diagnostics: We use the latest technology to diagnose your condition accurately ultrasound examinations to advanced imaging techniques. Individual therapy concepts: Each Patient is unique. Therefore, we can develop a customized treatment plan that takes into account your personal needs. Holistic approach: We support you not only medically, but also provide advice on diet, exercise and stress management, to strengthen your heart health in the long term. Psycho-social support: the Case of serious diseases emotional support is just as important as medical treatment. Our Team is available to you in each stage to page. Our offer includes the treatment of: Heart failure Coronary Heart Disease Heart rhythm disorders Heart valve defects Vascular disorders Take charge of your heart health in your hands! Let our experts advise you. An early Check‑up can save lives. Appointment: Call us at +49 XXX XXXXXXX or write an E‑Mail to info@beispielklinik.de. Visit our Website www.beispielklinik.de for more information. Your health is our priority. > Ektrak mula sa prutas ng cranberry Ektrak mula sa prutas ng appleberry Magnesium L-Arginin Ektrak mula sa dahon at bulaklak ng hawthorn Pulbos ng bulaklak ng hibiscus Ektrak mula sa dahon ng oliba Ektrak mula sa buto ng ubas Ektrak mula sa black currant Coenzyme Q10 Bitamina B6 Folate ![](https://cardio-balance-ph.store-best.net/img/5.jpg) <a href="http://chenxiaowei.com/uploadfile/in-diseases-of-the-cardiovascular-system-9757.xml">Presyong pang-promosyon</a> Minsan, dinadagdagan ng doktor ang base na therapy (mga gamot na kailangang inumin araw-araw) ng mga gamot na iniinom kapag may krisis, kapag ang presyon ay sobrang taas at biglang tumaas. At ang dosis ay pinipili rin nang napaka-indibidwal. Kaya imposible na sabihin kung alin ang pinakamahusay na gamot sa presyon, sa bawat kaso ay magkakaroon ng sariling kombinasyon na bagay sa iyo. <a href="http://urs-certification.com/gais/image/the-installed-disease-of-the-cardiovascular-disease.xml">Infusion of high blood pressure </a> ## The risk of cardiovascular disease in the young ## The risk of cardiovascular disease in the young: A growing challenge In the last decades has changed the Health of the young Generation. While cardiovascular diseases were perceived earlier, mainly as a Problem of elderly people, current studies show that young people — especially boys — are increasingly affected. This development raises the question: What causes it, and how can we reduce the risk? One of the main reasons for the Increase in the cardiovascular risk in young of life style. Many young people move too little: Instead of playing outside or playing sports, you will spend hours in front of the screen, whether it be in computer games or Surfing the Internet. The result: lack of exercise and Obesity, two major risk factors for heart problems. In addition, the diet plays a crucial role. The high consumption of Fast Food, sugary drinks and processed foods leads to increased blood pressure and unhealthy Cholesterol levels already at a young age. Studies show that boys are more prone than girls to such unhealthy eating habits, which increases your risk. Psychosocial factors should not be underestimated. The pressure in the school and the environment, which can lead to fear of social rejection and constant presence in social media to chronic Stress. Stress, in turn, can increase blood pressure and heart strain. Here, too, studies show that boys often speak less about their emotions and thus less help-seeking, which increases the burden. Another significant risk is the early consumption of tobacco and alcohol. Although the minimum age for the purchase of these products is regulated by law, access, many young people still in them. Tobacco is the blood Smoking damages your blood vessels and increases the risk for heart attacks, even in young people. What can be done to reverse this trend? He first measure is prevention. Schools should incorporate more movement in the classroom and a healthy diet to promote. Parents can set a good example by cooking together and actively spend time. In addition, it is important to give young people the opportunity to talk about Stress and mental strain — without being stigmatized. Health campaigns that are specifically tailored to the young, can help to create awareness of the issue. Sports clubs and municipalities should provide free or low-cost offers, to reach socially disadvantaged young people. In summary: The risk of cardiovascular disease in the young is not inevitable fate, but a Problem that can be addressed through targeted measures. It takes the joint efforts of parents, schools, organizations, and politics, to let the next Generation grow up more healthy. The time to Act is now. Would you like me to make a certain section in more detail or additional aspects into account? <a href="http://shell-moh.eu/uploads/assets/623-cardiovascular-disease-fighters.xml">The latest drugs for high blood pressure</a> ** Severe diseases of the cardiovascular System **. The latest drugs for high blood pressure High blood pressure, known medically as hypertension referred to, it represents a failure of a worldwide health problem and is considered to be one of the main risk factors for cardiovascular disease, including heart attack, stroke, and kidney. The continuous development of pharmacological therapy aims to lower the blood pressure effectively and to minimize the side effects. Current Medications Categories The current guidelines recommend the use of several classes of antihypertensive drugs as first choice. To include the latest developments, in particular: ARNi (Angiotensin Receptor Neprilysin Inhibitors) A prominent example of Sacubitril/Valsartan, a combination of a Neprilysin inhibitor and an Angiotensin‑II‑receptor antagonists. This drug showed in studies with a superior efficacy compared to conventional ACE inhibitors in patients with concomitant congestive heart failure. It promotes Natriuresis and vasodilation and thus lowers the blood pressure effectively. Endothelin Receptor Antagonists For special groups of patients, particularly in resistant hypertension, or in the case of simultaneous pulmonary hypertension, the investigation of such substances. They block the action of Endothelin 1, a powerful vasoconstrictor and leads to a blood vessel enlargement. Inhibitors of the mineralocorticoid receptor (MRAs) New selective MRAs as Finerenon are specifically designed for patients with type 2 Diabetes mellitus and chronic kidney disease developed. They not only reduce the blood pressure, but also protect the kidney function. Antisense oligonucleotides against Angiotensinogen This innovative therapeutic strategy aims at the reduction of the synthesis of Angiotensinogen in the liver. In early clinical studies, these substances showed a significant reduction in blood pressure after just one injection, which is a promising Option for patients with poor medication compliance. Monoclonal antibodies to Renin or other target structures Experimental approaches include monoclonal antibodies, which inhibit specific components of the Renin‑Angiotensin‑aldosterone system (RAAS). These drugs offer a longer duration of action and may have fewer side effects than conventional oral preparations. Clinical evidence and perspectives The latest studies, including the PARADIGM‑HF and FIDELIO‑DKD‑study confirm the efficacy and safety of these new substances. In particular, Sacubitril/Valsartan led to a significant reduction of cardiovascular deaths and hospitalizations in patients with heart failure. Despite the promising results, the challenges remain: Cost of new therapies; Long-term data on the safety; Identification of the optimal patient groups; possible interactions with other medications. Conclusion The development of new drugs against hypertension offers significant opportunities to improve patient care. In particular, the combination of different mechanisms of action and the introduction of innovative substances, such as Antisense therapeutics and monoclonal antibodies could in the future to revolutionize the treatment of resistant and komorbidem high blood pressure. Further research and long-term observational studies are necessary, however, to the full potential of these new therapies exploit. Would you like me to make a certain section in greater detail or further Details about a specific class of drugs to add? - [x] <a href="https://pad.mytga.de/s/lTOlK3YZ9">The latest drugs for high blood pressure</a> - [x] <a href="https://yodishit.com/uploads/userfiles/hypertension-of-plaques.xml">The risk of cardiovascular disease in the young</a> - [x] <a href="https://markdown.iv.cs.uni-bonn.de/s/GBcPBeZG9">Infusion of high blood pressure</a> - [x] <a href="http://sitpchemcieszyn.pl/_sitpchem/the-pathogenesis-of-cardiovascular-diseases.xml">http://sitpchemcieszyn.pl/_sitpchem/the-pathogenesis-of-cardiovascular-diseases.xml</a> <a href="https://hedgedoc.inqbus.de/s/yL6aDXKWS">https://hedgedoc.inqbus.de/s/yL6aDXKWS</a> <a href="https://hedgedoc.syyrell.com/s/VU0T2fR8tI">https://hedgedoc.syyrell.com/s/VU0T2fR8tI</a> <a href="https://pad.demokratie-dialog.de/s/fUa_8sol47">https://pad.demokratie-dialog.de/s/fUa_8sol47</a> <a href="https://md.cortext.net/s/9rrBkuArV">https://md.cortext.net/s/9rrBkuArV</a> <a href="https://hd.platypwnies.de/s/-UFS2xaVcQ">https://hd.platypwnies.de/s/-UFS2xaVcQ</a> <a href="https://hedgedoc.stusta.de/s/dJ8om_hKO">https://hedgedoc.stusta.de/s/dJ8om_hKO</a> <a href="https://pad.dominick-leppich.de/s/MMczWXtgu">https://pad.dominick-leppich.de/s/MMczWXtgu</a> <a href="https://pad.data.coop/s/b7q3jtOe2">https://pad.data.coop/s/b7q3jtOe2</a> <a href="https://hedgedoc.team23.org/s/jQ7A3EpomM">https://hedgedoc.team23.org/s/jQ7A3EpomM</a> <a href="https://hedgedoc.obermui.de/s/zDRVuKnwg4">https://hedgedoc.obermui.de/s/zDRVuKnwg4</a> <a href="https://doc.spiegie.de/s/GdgRkP5aZ">https://doc.spiegie.de/s/GdgRkP5aZ</a> <a href="https://pad.geolab.space/s/SF8lZRkDR">https://pad.geolab.space/s/SF8lZRkDR</a> <a href="https://doc.cisti.org/s/b-f8LvB9Xw">https://doc.cisti.org/s/b-f8LvB9Xw</a> <a href="https://pads.dgnum.eu/s/d_JRMNxjsI">https://pads.dgnum.eu/s/d_JRMNxjsI</a> <a href="https://hedgedoc.faimaison.net/s/fSfnENKS-s">https://hedgedoc.faimaison.net/s/fSfnENKS-s</a> <a href="https://n.jo-so.de/s/AFCBb96Oc">https://n.jo-so.de/s/AFCBb96Oc</a> <a href="https://pad.stuve.de/s/a_5YZ75xC">https://pad.stuve.de/s/a_5YZ75xC</a> <a href="https://pad.aleph.world/s/RDt5VWLf1">https://pad.aleph.world/s/RDt5VWLf1</a> <a href="https://notas.gaiacoop.tech/s/DFiLSpuBy">https://notas.gaiacoop.tech/s/DFiLSpuBy</a> <a href="https://md.studibla.ch/s/j8F2XghuLb">https://md.studibla.ch/s/j8F2XghuLb</a> <a href="https://notes.rabjerg.de/s/rkDlpwcfzg">https://notes.rabjerg.de/s/rkDlpwcfzg</a> <a href="https://doc.hkispace.com/s/kw0HA6wml">https://doc.hkispace.com/s/kw0HA6wml</a> <a href="https://notes.llgoewer.de/s/zjAAf1XAj">https://notes.llgoewer.de/s/zjAAf1XAj</a> <a href="https://md.eris.cc/s/Wfd2n-J1ir">https://md.eris.cc/s/Wfd2n-J1ir</a> <a href="https://doc.interscalar.eu/s/6Sdj7Sxjf">https://doc.interscalar.eu/s/6Sdj7Sxjf</a> <a href="https://pads.cantorgymnasium.de/s/fr2VZnv-s">https://pads.cantorgymnasium.de/s/fr2VZnv-s</a> <a href="https://pad.c3voc.de/s/UGrw-s0JH">https://pad.c3voc.de/s/UGrw-s0JH</a> <a href="https://www.notizen.kita.bayern/s/FrHiel2pfJ">https://www.notizen.kita.bayern/s/FrHiel2pfJ</a> <a href="https://hedgedoc.ichmann.de/s/C6R86Bs-MD">https://hedgedoc.ichmann.de/s/C6R86Bs-MD</a> <a href="https://doc.neutrinet.be/s/T8Uxn2IQBG">https://doc.neutrinet.be/s/T8Uxn2IQBG</a> <a href="https://hedgedoc.timon.ch/s/iIcE1G8Pq">https://hedgedoc.timon.ch/s/iIcE1G8Pq</a> <a href="https://hedgedoc.private.coffee/s/Bn0-neBMB">https://hedgedoc.private.coffee/s/Bn0-neBMB</a> <a href="https://pad.gusted.xyz/s/XniF5K6YB">https://pad.gusted.xyz/s/XniF5K6YB</a> <a href="https://pad.eisfunke.com/s/v0NS4GgHAw">https://pad.eisfunke.com/s/v0NS4GgHAw</a> <a href="https://pad.wolkenbar.de/s/-5Fw01Z5WR">https://pad.wolkenbar.de/s/-5Fw01Z5WR</a> <a href="https://pads.tobast.fr/s/cSdm8A8DIM">https://pads.tobast.fr/s/cSdm8A8DIM</a> <a href="https://hd.wedler.me/s/1ZbsRR0c2">https://hd.wedler.me/s/1ZbsRR0c2</a> <a href="https://md.micronited.de/s/Sk0M6D9Gfx">https://md.micronited.de/s/Sk0M6D9Gfx</a> <a href="https://md.giplt.nl/s/hpjY2f9JDu">https://md.giplt.nl/s/hpjY2f9JDu</a> <a href="https://doc.fsr.saarland/s/_VCd0CuaJP">https://doc.fsr.saarland/s/_VCd0CuaJP</a> <a href="https://hdoc.csirt-tooling.org/s/91ABpWXNzm">https://hdoc.csirt-tooling.org/s/91ABpWXNzm</a> <a href="https://md.chaosdorf.de/s/N_z-JybRIg">https://md.chaosdorf.de/s/N_z-JybRIg</a> <a href="https://om-office.de/s/rJLmTw5MGx">https://om-office.de/s/rJLmTw5MGx</a> <a href="https://editor.celtoi.org/s/aFHjdToB2">https://editor.celtoi.org/s/aFHjdToB2</a> <a href="https://md.coredump.ch/s/G0AFHA92R">https://md.coredump.ch/s/G0AFHA92R</a> <a href="https://docs.snowdrift.coop/s/wMoaHjA3G">https://docs.snowdrift.coop/s/wMoaHjA3G</a> <a href="https://doc.projectsegfau.lt/s/lEoC2ZfTGz">https://doc.projectsegfau.lt/s/lEoC2ZfTGz</a> <a href="https://hedgedoc.stanleysolutionsnw.com/s/gZLIDtSYtE">https://hedgedoc.stanleysolutionsnw.com/s/gZLIDtSYtE</a> <a href="https://markdown.iv.cs.uni-bonn.de/s/v2XnyFqjC">https://markdown.iv.cs.uni-bonn.de/s/v2XnyFqjC</a> <a href="https://pad.mytga.de/s/oaELuWDoQU">https://pad.mytga.de/s/oaELuWDoQU</a> <a href="https://notas.laotra.red/s/i43jDnxSc8">https://notas.laotra.red/s/i43jDnxSc8</a> <a href="https://hedgedoc.digilol.net/s/YrE6tL_85c">https://hedgedoc.digilol.net/s/YrE6tL_85c</a> <a href="https://pad.mytga.de/s/8Afn4ezDa">https://pad.mytga.de/s/8Afn4ezDa</a> <a href="https://pad.hxx.cz/s/8hLqaKGMyQ">https://pad.hxx.cz/s/8hLqaKGMyQ</a> <a href="https://pad.deckenpfronn.info/s/ve07ZATJ0">https://pad.deckenpfronn.info/s/ve07ZATJ0</a> <a href="https://pad.medialepfade.net/s/OebLPoNal">https://pad.medialepfade.net/s/OebLPoNal</a> <a href="https://hedgedoc.c3d2.de/s/hEdqh3Cpev">https://hedgedoc.c3d2.de/s/hEdqh3Cpev</a> <a href="https://notes.ip2i.in2p3.fr/s/SeKqMXDp6">https://notes.ip2i.in2p3.fr/s/SeKqMXDp6</a> <a href="https://pad.sra.uni-hannover.de/s/F5P-oIAe3r">https://pad.sra.uni-hannover.de/s/F5P-oIAe3r</a> <a href="https://md.rappet.xyz/s/_Qss8e1Cbx">https://md.rappet.xyz/s/_Qss8e1Cbx</a> <a href="https://pad.yuka.dev/s/wIcHvzcW8G">https://pad.yuka.dev/s/wIcHvzcW8G</a> <a href="https://hedgedoc.et.aksw.org/s/A4MKDwk9z">https://hedgedoc.et.aksw.org/s/A4MKDwk9z</a> <a href="https://md.mandragot.org/s/THv9tHaFAK">https://md.mandragot.org/s/THv9tHaFAK</a> <a href="https://hackmd.hub.yt/s/Z-t1Mfegc">https://hackmd.hub.yt/s/Z-t1Mfegc</a> <a href="https://codimd.pirati.cz/s/WlNYQ5ajC">https://codimd.pirati.cz/s/WlNYQ5ajC</a> <a href="https://notes.medien.rwth-aachen.de/s/eVC2u4n-hg">https://notes.medien.rwth-aachen.de/s/eVC2u4n-hg</a> <a href="https://hedgedoc.stura-ilmenau.de/s/ye3af1assd">https://hedgedoc.stura-ilmenau.de/s/ye3af1assd</a> <a href="https://notes.phys-el.ru/s/jO5qZqtMoM">https://notes.phys-el.ru/s/jO5qZqtMoM</a> <a href="https://hedgedoc.ctf.mcgill.ca/s/0Ht3HtjE9">https://hedgedoc.ctf.mcgill.ca/s/0Ht3HtjE9</a> <a href="https://hedgedoc.eclair.ec-lyon.fr/s/9iUEo8jCi8">https://hedgedoc.eclair.ec-lyon.fr/s/9iUEo8jCi8</a> <a href="https://hackmd.openmole.org/s/-RNFpobnh">https://hackmd.openmole.org/s/-RNFpobnh</a> <a href="https://doc.hkispace.com/s/eKGGwl5wQ">https://doc.hkispace.com/s/eKGGwl5wQ</a> <a href="https://hedgedoc.auro.re/s/liVAd22HXB">https://hedgedoc.auro.re/s/liVAd22HXB</a> <a href="https://notes.simeonreusch.com/s/6C0k91Sg_">https://notes.simeonreusch.com/s/6C0k91Sg_</a> <a href="https://md.bytewerk.org/s/8d9OD19HQF">https://md.bytewerk.org/s/8d9OD19HQF</a> <a href="https://docs.aix.inrae.fr/s/OIax-Nhd1">https://docs.aix.inrae.fr/s/OIax-Nhd1</a> <a href="https://docs.localcharts.org/s/bjJGFif3J">https://docs.localcharts.org/s/bjJGFif3J</a> <a href="https://hedgedoc.jcg.re/s/_Hr9l9Z8MF">https://hedgedoc.jcg.re/s/_Hr9l9Z8MF</a> <a href="https://pad.flipdot.org/s/UXVlyKWBkd">https://pad.flipdot.org/s/UXVlyKWBkd</a> <a href="https://doc.gnuragist.es/s/PZsp0udh4R">https://doc.gnuragist.es/s/PZsp0udh4R</a> <a href="https://hedgedoc.ggu.cz/s/fkFhFRcFfv">https://hedgedoc.ggu.cz/s/fkFhFRcFfv</a> <a href="https://md.softwarefreedom.net/s/vJggXHfbI">https://md.softwarefreedom.net/s/vJggXHfbI</a> <a href="https://pad.sigflag.at/s/I2dJaoBeE">https://pad.sigflag.at/s/I2dJaoBeE</a> <a href="https://pad.n39.eu/s/oEKN_Yl0ik">https://pad.n39.eu/s/oEKN_Yl0ik</a> <a href="https://doc.interscalar.eu/s/gdQAW5ZSi">https://doc.interscalar.eu/s/gdQAW5ZSi</a> <a href="https://edit.leiden.digital/s/WcoJA02S4j">https://edit.leiden.digital/s/WcoJA02S4j</a> <a href="https://md.sebastians.dev/s/B99tBZVqW">https://md.sebastians.dev/s/B99tBZVqW</a> <a href="https://pad.fablab-siegen.de/s/s2TBdLHxZ8">https://pad.fablab-siegen.de/s/s2TBdLHxZ8</a> ## Infusion of high blood pressure ## Infusion therapy in hypertensive crisis: indications and pharmacotherapy Introduction High blood pressure (arterial hypertension) represents a worldwide health problem that can result in insufficient control to serious complications such as stroke, heart attack, or kidney failure. A hypertensive crisis is when the systolic blood pressure rises above 180 mmHg and/or diastolic over 120 mmHg, accompanied by signs of organ involvement (hypertensive emergency) or excluding (hypertensive urge situation). In the case of a hypertensive Emergency, a fast, controlled blood pressure reduction is required, in order to prevent acute organ damage. For this purpose, the parenteral administration of drugs, in particular, the infusion therapy is used. Indications for infusion therapy Infusion therapy is the primary recommended in the following situations: hypertensive emergency with signs of endorganer injury (e.g., acute coronary syndrome, aortic dissection, acute renal failure, encephalopathy); Inability to oral medication intake (e.g. due to Nausea, vomiting, or loss of consciousness); poor response to oral antihypertensive therapy for severe increase in blood pressure. Continuous Infusion Medications The choice of the drug depends on the present comorbidity and the institution concerned. The most common substances for Infusion in hypertensive crisis are: Nitroglycerin: Mechanism of action: venodilatorische and (in higher doses) arterioläre effect; Indication: acute coronary syndrome, congestive heart failure with pulmonary edema; Dosage: initial 5-10 µg/min, gradually increasing to blood pressure control. Nicardipine (A Calcium Channel Blocker): Mechanism of action: selective arterioläre Dilatation; Indication: General hypertensive crisis, especially in patients with cerebrovascular risks; Dosage: 5 mg/h, if necessary, every 5-15 minutes to 2.5 mg/h, increase (max. 15 mg/h). Labetalol (α-/β‑blockers): Mechanism of action: a combined α‑ and β‑adrenergic Blockade; Indication: aortic dissection, stroke (in the case of controlled reduction), pre-eclampsia; Dosage: Bolus of 20 mg, then Infusion of 1-2 mg/min. Esmolol (short-term β₁‑blockers): Mechanism of action: selective β₁‑adrenergic Blockade with a very short half-life; Indication: aortic dissection, postoperative hypertension; Dosage: Bolus of 500 µg/kg, then Infusion of 50-200 µg/kg/min. Therapeutic objectives and Monitoring The primary objective of the infusion therapy in the absence of rapid normalization of blood pressure, but a controlled reduction is: in the first hour: reduction of the mean arterial pressure (MAP) by more than 25%; stabilized condition: Achieve a target pressure of ≤160/100 mmHg within 2-6 hours; continuous Monitoring of blood pressure (invasive or non‑invasive measurement), heart rate, oxygen saturation, and renal function. Conclusion The infusion therapy in hypertensive crisis is an essential therapeutic tool, especially if there is a fast and controlled reduction of blood pressure is essential to life. The careful selection of the infusion preparation, taking into account the individual patient's situation and the close Monitoring during therapy are crucial to the success and the avoidance of side effects.